Cisplatin and ototoxicity in childhood: the perspective of supporting otoprotective agentes.


Journal

Brazilian journal of biology = Revista brasleira de biologia
ISSN: 1678-4375
Titre abrégé: Braz J Biol
Pays: Brazil
ID NLM: 101129542

Informations de publication

Date de publication:
2024
Historique:
received: 01 10 2023
accepted: 05 06 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: epublish

Résumé

Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The ototoxic effect in the pediatric population has a bigger impact as it compromises language acquisition. The discovery of drugs with otoprotective effects and the optimal way to administer them have become significant challenges in minimizing the impact of cisplatin regarding auditory function. The objective was to understand otoprotective drugs and their relevance in the preventive treatment to cisplatin-induced ototoxicity in childhood. An integrative review was conducted by consulting databases including PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov. The search strategy was performed by crossing descriptors (DeCS and MeSH) and free terms. Studies published in English, Spanish, and Portuguese were selected, with no publication year restrictions. Subsequently, articles were selected according to inclusion and exclusion criteria. A total of 736 articles were found in PubMed, 431 in Bireme, 425 in MedLine, 6 in LILACS, 0 in SciELO, and 4 in ClinicalTrials.gov. After document analysis, 12 articles were selected for full analysis. Evidence was found for 8 substances with potential otoprotective effects when used with cisplatin, which tend to minimize the impact of cisplatin regarding auditory function. The substances found were: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin also Sodium Thiosulfate. In general, these drugs are applied before, during, or after cisplatin infusion, depending on the chosen drug, via intravenous, oral, or transtympanic injections, acting as antioxidant therapy. The biochemical effects of these substances are relevant to their potential otoprotective properties, including the inactivation of oxygen free radicals and electrophilic platinum species. The use of these substances can reduce ototoxicity, decreasing cisplatin-induced hearing loss and improving the confort of life, especially for children.

Identifiants

pubmed: 39140499
pii: S1519-69842024000101216
doi: 10.1590/1519-6984.279117
pii:
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Antineoplastic Agents 0
Protective Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e279117

Auteurs

A G F S Araujo (AGFS)

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

J C Silva (JC)

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

E M Trindade Filho (EM)

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

J C Silva (JC)

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

K D A Gama (KDA)

Centro Universitário CESMAC, Maceió, AL, Brasil.

M A M Bandeira (MAM)

Universidade Federal do Ceará - UFC, Fortaleza, CE, Brasil.

W A Silva (WA)

Universidade Federal do Ceará - UFC, Fortaleza, CE, Brasil.

K C Mousinho (KC)

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.
Centro Universitário CESMAC, Maceió, AL, Brasil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH